Payment overview · 2025
General Payments
$299.99
14 reported records · 8 companies
Healthcare provider profile · identity verified
Ryan M. Cahill, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DEER PARK, NY · NPI 1437250032
Verified facts
What the public records show
CMS Open Payments records show Ryan M. Cahill, D.O. received $299.99 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.07 | 22.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.87 | 15.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.16 | 14.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.93 | 12.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.21 | 11.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.16 | 10.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.70 | 8.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.89 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.99 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $77.03 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 73 |
| Gabapentin | Gabapentin | 374 | 44 |
| Furosemide | Furosemide | 336 | 44 |
| Eliquis | Apixaban | 278 | 36 |
| Sertraline Hcl | Sertraline Hcl | 239 | 35 |
| Famotidine | Famotidine | 231 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 38 |
| Losartan Potassium | Losartan Potassium | 214 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 51 |
| Allopurinol | Allopurinol | 157 | 27 |
| Mirtazapine | Mirtazapine | 153 | 17 |
| Lisinopril | Lisinopril | 151 | 33 |
| Potassium Chloride | Potassium Chloride | 143 | 28 |
| Simvastatin | Simvastatin | 140 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 23 |
| Jardiance | Empagliflozin | 118 | 19 |
| Ezetimibe | Ezetimibe | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 28 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 23 |
| Memantine Hcl | Memantine Hcl | 97 | suppressed |
| Omeprazole | Omeprazole | 95 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | suppressed |
| Baclofen | Baclofen | 79 | 15 |
| Montelukast Sodium | Montelukast Sodium | 77 | 23 |
| Prednisone | Prednisone | 77 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 11 |
| Donepezil Hcl | Donepezil Hcl | 75 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 37 |
| Carvedilol | Carvedilol | 72 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 22 |
| Metformin Hcl Er | Metformin Hcl | 70 | 16 |
| Finasteride | Finasteride | 67 | suppressed |
| Fentanyl | Fentanyl | 64 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 11 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 56 | suppressed |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Alprazolam | Alprazolam | 53 | 19 |
| Trazodone Hcl | Trazodone Hcl | 53 | suppressed |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Sucralfate | Sucralfate | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 14 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Ramipril | Ramipril | 49 | 16 |
| Synthroid | Levothyroxine Sodium | 49 | 17 |
| Budesonide | Budesonide | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Brilinta | Ticagrelor | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 12 |
| Lokelma | Sodium Zirconium Cyclosilicate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Valsartan | Valsartan | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 17 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | 12 |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 29 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 23 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Glipizide | Glipizide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Ciprofloxacin-D5w | Ciprofloxacin In 5 % Dextrose | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.99 · 14 records | Lilly USA, LLC | Cologuard Collection Kit, INSPIRE, JARDIANCE, MOUNJARO, OFEV, Ozempic, REXULTI, SYNTHROID, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error